Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex vs Arimidex in HR+ advanced breast cancer
NCT01602380Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by AstraZeneca. Started Oct 2012; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01602380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01602380.